Agile Therapeutics (NASDAQ:AGRX) Stock Price Down 5.5%

Agile Therapeutics Inc (NASDAQ:AGRX) traded down 5.5% during trading on Wednesday . The company traded as low as $1.04 and last traded at $1.04, 1,450,683 shares changed hands during trading. An increase of 231% from the average session volume of 438,323 shares. The stock had previously closed at $1.10.

A number of equities research analysts have recently commented on the stock. ValuEngine cut shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Maxim Group set a $3.00 price objective on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 10th. Zacks Investment Research raised shares of Agile Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 price objective on the stock in a research note on Tuesday, August 6th. Finally, Oppenheimer assumed coverage on shares of Agile Therapeutics in a research note on Thursday, June 6th. They set an “outperform” rating and a $5.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $3.45.

The business’s 50 day moving average is $1.18 and its 200-day moving average is $1.34. The stock has a market cap of $49.26 million, a price-to-earnings ratio of -1.79 and a beta of 0.42.



Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, sell-side analysts forecast that Agile Therapeutics Inc will post -0.37 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC grew its stake in Agile Therapeutics by 7.9% in the 2nd quarter. Acadian Asset Management LLC now owns 450,180 shares of the specialty pharmaceutical company’s stock valued at $657,000 after acquiring an additional 32,911 shares during the period. BlackRock Inc. grew its stake in Agile Therapeutics by 27.2% in the 2nd quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock valued at $247,000 after acquiring an additional 36,212 shares during the period. JPMorgan Chase & Co. grew its stake in Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock valued at $108,000 after acquiring an additional 73,238 shares during the period. Renaissance Technologies LLC grew its stake in Agile Therapeutics by 5.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock valued at $3,291,000 after acquiring an additional 120,403 shares during the period. Finally, Vanguard Group Inc. grew its stake in Agile Therapeutics by 129.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after acquiring an additional 978,672 shares during the period. 43.73% of the stock is currently owned by hedge funds and other institutional investors.

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Read More: How prevalent are 12b-1 fees?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.